I am a
Home I AM A Search Login

Papers of the Week

Papers: 17 Feb 2024 - 23 Feb 2024

2024 Feb 21

Clin Drug Investig


Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.


Thaliffdeen R, Yu A, Rascati K


Two oral calcitonin gene-related peptide (CGRP) antagonists, atogepant and rimegepant, were approved in 2021 for the preventive treatment of episodic migraine (EM), yet no formal cost-effectiveness analysis has been published. The objective of this study was to evaluate the cost-effectiveness of atogepant 60 mg and rimegepant 75 mg compared with placebo.